Adriamycin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer

A. Ardizzoni, L. Canobbio, P. Pronzato, L. Repetto, J. Serrano, F. Benvenuto, C. Simonassi, F. Baracco, B. Faravelli, M. Nosenzo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Thirty-five small cell lung cancer (SCLC) patients were treated with combination chemotherapy including adriamycin, cyclophosphamide, etoposide (ACE). Out of 32 evaluable patients there were 21.9% complete responses and 53.1% partial responses with an overall median survival of 37 weeks (50 weeks for patients with limited disease and 34 weeks for patients with extended disease). Toxicity was generally well tolerated. In conclusion the ACE regimen results in being active and safe in the treatment of SCLC.

Original languageEnglish
Pages (from-to)416-419
Number of pages4
JournalChemioterapia
Volume5
Issue number6
Publication statusPublished - 1986

Fingerprint

Small Cell Lung Carcinoma
Etoposide
Doxorubicin
Cyclophosphamide
Therapeutics
Combination Drug Therapy
Survival

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Cite this

Ardizzoni, A., Canobbio, L., Pronzato, P., Repetto, L., Serrano, J., Benvenuto, F., ... Nosenzo, M. (1986). Adriamycin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer. Chemioterapia, 5(6), 416-419.

Adriamycin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer. / Ardizzoni, A.; Canobbio, L.; Pronzato, P.; Repetto, L.; Serrano, J.; Benvenuto, F.; Simonassi, C.; Baracco, F.; Faravelli, B.; Nosenzo, M.

In: Chemioterapia, Vol. 5, No. 6, 1986, p. 416-419.

Research output: Contribution to journalArticle

Ardizzoni, A, Canobbio, L, Pronzato, P, Repetto, L, Serrano, J, Benvenuto, F, Simonassi, C, Baracco, F, Faravelli, B & Nosenzo, M 1986, 'Adriamycin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer', Chemioterapia, vol. 5, no. 6, pp. 416-419.
Ardizzoni A, Canobbio L, Pronzato P, Repetto L, Serrano J, Benvenuto F et al. Adriamycin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer. Chemioterapia. 1986;5(6):416-419.
Ardizzoni, A. ; Canobbio, L. ; Pronzato, P. ; Repetto, L. ; Serrano, J. ; Benvenuto, F. ; Simonassi, C. ; Baracco, F. ; Faravelli, B. ; Nosenzo, M. / Adriamycin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer. In: Chemioterapia. 1986 ; Vol. 5, No. 6. pp. 416-419.
@article{65bd801ba1004ed6909eca00275fc125,
title = "Adriamycin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer",
abstract = "Thirty-five small cell lung cancer (SCLC) patients were treated with combination chemotherapy including adriamycin, cyclophosphamide, etoposide (ACE). Out of 32 evaluable patients there were 21.9{\%} complete responses and 53.1{\%} partial responses with an overall median survival of 37 weeks (50 weeks for patients with limited disease and 34 weeks for patients with extended disease). Toxicity was generally well tolerated. In conclusion the ACE regimen results in being active and safe in the treatment of SCLC.",
author = "A. Ardizzoni and L. Canobbio and P. Pronzato and L. Repetto and J. Serrano and F. Benvenuto and C. Simonassi and F. Baracco and B. Faravelli and M. Nosenzo",
year = "1986",
language = "English",
volume = "5",
pages = "416--419",
journal = "Chemioterapia",
issn = "0392-906X",
publisher = "Editrice Giuntina",
number = "6",

}

TY - JOUR

T1 - Adriamycin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer

AU - Ardizzoni, A.

AU - Canobbio, L.

AU - Pronzato, P.

AU - Repetto, L.

AU - Serrano, J.

AU - Benvenuto, F.

AU - Simonassi, C.

AU - Baracco, F.

AU - Faravelli, B.

AU - Nosenzo, M.

PY - 1986

Y1 - 1986

N2 - Thirty-five small cell lung cancer (SCLC) patients were treated with combination chemotherapy including adriamycin, cyclophosphamide, etoposide (ACE). Out of 32 evaluable patients there were 21.9% complete responses and 53.1% partial responses with an overall median survival of 37 weeks (50 weeks for patients with limited disease and 34 weeks for patients with extended disease). Toxicity was generally well tolerated. In conclusion the ACE regimen results in being active and safe in the treatment of SCLC.

AB - Thirty-five small cell lung cancer (SCLC) patients were treated with combination chemotherapy including adriamycin, cyclophosphamide, etoposide (ACE). Out of 32 evaluable patients there were 21.9% complete responses and 53.1% partial responses with an overall median survival of 37 weeks (50 weeks for patients with limited disease and 34 weeks for patients with extended disease). Toxicity was generally well tolerated. In conclusion the ACE regimen results in being active and safe in the treatment of SCLC.

UR - http://www.scopus.com/inward/record.url?scp=0022843849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022843849&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 416

EP - 419

JO - Chemioterapia

JF - Chemioterapia

SN - 0392-906X

IS - 6

ER -